NCT01604928View on ClinicalTrials.gov

Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder

PHASE2CompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

April 5, 2004

Primary Completion Date

January 25, 2005

Study Completion Date

January 25, 2005

Conditions
Urinary Bladder, Overactive
Interventions
DRUG

YM178

Oral

DRUG

tolterodine

Oral

DRUG

Placebo

Oral

Trial Locations (30)

1090

Site: 12, Brussels

2650

Site: 13, Edegem

3000

Site: 10, Leuven

9000

Site: 11, Ghent

19230

Site: 34, Hagenow

20253

Site: 33, Hamburg

28046

Site: 40, Madrid

40001

Site: 21, Ústí nad Labem

46600

Site: 42, Alzira-Valencia

54290

Site: 31, Trier

56068

Site: 36, Koblenz

56130

Site: 32, Bad Ems

60326

Site: 35, Frankfurt

79312

Site: 30, Emmendingen

276 01

Site: 25, Mělník

128 08

Site: 22, Prague

140 59

Site: 24, Prague

180 81

Site: 20, Prague

401 13

Site: 23, Ústí nad Labem

09200

Site: 43, Miranda de Ebro

413 45

Site: 55, Gothenburg

582 24

Site: 53, Linköping

221 85

Site: 50, Lund

141 86

Site: 51, Stockholm

751 85

Site: 52, Uppsala

B15 2TG

Site: 64, Bimingham

N19 5LW

Site: 62, London

W1P 7PN

Site: 63, London

S10 2JF

Site: 60, Sheffield

SA6 6NL

Site: 61, Swansea

All Listed Sponsors
lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT01604928 - Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder | Biotech Hunter | Biotech Hunter